Astrotech Corporation was formed in 1984. The company is engaged in the space commerce activities. The company has supported the launch of 23 shuttle missions and about 300 spacecraft; built space hardware and processing facilities; constructed and operated processing facilities; and prepared and processed scientific research for microgravity. Its business unit includes Astrotech Space Operations (ASO). ASO provides spacecraft support services for its government and commercial customers to successfully process complex communication, earth observation and deep space satellites in preparation for their launch on a variety of launch vehicles. Processing activities include satellite ground transportation; pre-launch hardware integration and testing; satellite encapsulation, fueling and launch pad delivery; and communication linked launch control. Its ASO facilities can process five meter class satellites accommodating the majority of U.S. based satellite preparation programs. ASO's service capabilities include designing and building spacecraft processing equipment and facilities. In addition, ASO provides propellant services including designing, building and testing propellant service equipment for fueling spacecraft. ASO accounted for 99% of its consolidated revenues for the year ended June 30, 2013. Its other business unit is a technology incubator designed to commercialize space-industry technologies. This business unit it currently pursuing two distinct opportunities: 1st Detect - It designs, manufactures and sells miniature mass spectrometer equipment. 1st Detect launched the MMS-1000 during March 2012. The MMS-1000 is a low power, miniature mass spectrometer device designed initially for the laboratory testing market. The design of this unit is the result of the Company's work with National Aeronautics and Space Administration ('NASA') on the International Space Station. Astrogenetix - It is a biotechnology company formed to commercialize products processed in the environment of microgravity. Astrogenetix pursued an aggressive space access strategy to take advantage of the Space Shuttle program prior to its retirement in 2011. This strategy gave Astrogenetix unprecedented access to research in microgravity, as the Company flew experiments twelve times over a three year period. Astrogenetix is currently researching a Salmonella vaccine as part of its ongoing commercialization strategy. Concurrently, Astrogenetix is evaluating a vaccine target for Methicilin-Resistant Staphylococcus Aureus ('MRSA') based on discoveries made in microgravity. In December 2011, the Company negotiated a Space Act Agreement with NASA for a minimum of twenty eight additional space flights. It is subject to United States federal, state, and local laws and regulations designed to protect the environment and to regulate the discharge of materials into the environment.